Table 3.

Clinical characteristics of patients with MA-ILD who failed conventional treatment and received adjunctive tacrolimus (n = 18). Values are n unless otherwise specified.

Clinical CharacteristicsResponders, n = 13No Response, n = 5p
Age at onset of myositis, yrs41.843.01.00
Smoking history
Baseline CK, U/l4353.51975.70.60
Baseline aldolase31.043.80.64
Serologic data
PFT, %
CT chest
  Honeycombing absent950.23
  Honeycombing present40
Lung histopathology
Conventional DMARD
  • * COP with NSIP, COP with hypersensitivity pneumonitis, and COP with diffuse alveolar damage. MA-ILD: myositis-associated interstitial lung disease; CADM: clinically amyopathic dermatomyositis; CK: creatine kinase; ANA: antinuclear antibody; SRP: signal recognition particle; PFT: pulmonary function test; FVC: forced vital capacity; TLC: total lung capacity; CT: computed tomography; COP: cryptogenic organizing pneumonia; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; DMARD: disease-modifying antirheumatic drugs; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil; N/A: not applicable.